Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?

When MRNA reports fourth-quarter earnings, investors will likely focus on pipeline updates.

MRKNegative Net Change MRNANegative Net Change SRPTPositive Net Change CRSPPositive Net Change

Zacks Equity Research

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.

PFEPositive Net Change CTMXPositive Net Change CSTLPositive Net Change ERASNegative Net Change

Zacks Equity Research

Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab

MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.

MRNANegative Net Change NVAXNegative Net Change CVACNegative Net Change

Sundeep Ganoria

How to Play Moderna Stock After the Recent Sales Guidance Cut

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

GSKNegative Net Change PFEPositive Net Change MRKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.

MRKNegative Net Change MRNANegative Net Change CTMXPositive Net Change CSTLPositive Net Change

Zacks Equity Research

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.

VRTXPositive Net Change MRNANegative Net Change CTMXPositive Net Change CSTLPositive Net Change

Sundeep Ganoria

Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

GSKNegative Net Change PFEPositive Net Change MRKNegative Net Change MRNANegative Net Change

Zacks Equity Research

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.

SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change